Menu
← Oncology Approval Tracker
FDA DECISION ·
Aucatzyl
obecabtagene autoleucel · Autolus
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
LAMPGEN ANALYSIS
Why it matters
This CD19 CAR T product adds another cellular therapy option for adults with difficult-to-treat B-cell ALL.
What research teams should watch
Track pretreatment marrow blast burden and the resulting split-dose schedule; coordinate manufacturing, bridging and inpatient readiness.
PRIMARY RECORDS